Butterfly Network (BFLY) Stock Forecast & Price Target

Butterfly Network is supported by a differentiated cMUT semiconductor platform that enables whole-body imaging with a single handheld probe at lower cost than traditional ultrasound, helping it gain share in point-of-care markets. Its Embedded strategy is especially compelling because 12 partnerships can generate upfront fees, license revenue, chip sales, and eventual revenue-sharing, with Embedded revenue reaching 33% of total sales in 2Q26 and management targeting a $500 million revenue trajectory in 2030. The core business also has multiple catalysts, including a next-generation iQ launch in 1Q27, Garden applications in 2H26, and a strong balance sheet with $125 million in cash and no debt, which supports operating leverage and a path toward free cash flow breakeven in 2027.

Butterfly Network is viewed negatively because its growth could slow as Embedded partnerships take longer to commercialize, leaving operating expense leverage stalled and core business revenue still accounting for about 2/3 of revenue mix as of 2Q26. Competitive pressure is also intense, with larger ultrasound players such as GE Healthcare, Philips, Siemens Healthineers, and United Imaging able to use scale and enterprise relationships to limit Butterfly’s share in POCUS. Although Butterfly has $125 million in cash and investments and no debt, it is still not profitable, expects FCF breakeven in 2027, and trades at a 2026 EV/sales multiple of 15.5x, a steep premium versus peers.